Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 11, 2009, Pages 1864-1873

  Tran, Thuy A ^a   Rosik, Daniel ^b   Abrahmsén, Lars ^b   Sandström, Mattias ^c   Sjöberg, Anna ^b   Wållberg, Helena ^d   Ahlgren, Sara ^e   Orlova, Anna ^a,b   Tolmachev, Vladimir ^a,b,e  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecules; HER2; Imaging; Peptide synthesis

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; INDIUM 111; PEP 05352; PEP 05352 TC 99M; PEP 05541; PEP 05541 IN 111; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; SCINTILLATION CAMERA; SOLID PHASE SYNTHESIS; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CELL LINE, TUMOR; DRUG DESIGN; FEMALE; HUMANS; ISOTOPE LABELING; KINETICS; MICE; MOLECULAR IMAGING; MOLECULAR SEQUENCE DATA; NEOPLASMS; RADIOACTIVE TRACERS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION;

EID: 72149106173     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1176-z     Document Type: Article

References (33)

1. PA Nygren 2008 Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold FEBS J 275 2668 2676 10.1111/j.1742-4658.2008.06438.x 10.1111/j.1742-4658.2008.06438.x 1:CAS:528:DC%2BD1cXnt1CjsrY%3D 18435759 (Pubitemid 351678678)
2. Tran T, Tolmachev V. Affibody molecules, a new class of targeting agents for molecular imaging. In: Chen X, editor. Recent advances of bioconjugation chemistry in molecular imaging. Kerala, India: Research Signpost; 2008. p. 1-17.
3. V Tolmachev A Orlova FY Nilsson J Feldwisch A Wennborg L Abrahmsén 2007 Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy Expert Opin Biol Ther 7 555 568 10.1517/14712598.7.4.555 10.1517/14712598.7.4.555 1:CAS:528:DC%2BD2sXjt1yns78%3D 17373906 (Pubitemid 46524679)
4. A Orlova H Wållberg S Stone-Elander V Tolmachev 2009 On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of 124I-labelled affibody molecule and trastuzumab in a murine xenograft model J Nucl Med 50 417 425 10.2967/jnumed.108.057919 10.2967/jnumed.108.057919 1:CAS:528:DC%2BD1MXktVynsro%3D 19223403
5. V Tolmachev 2008 Imaging of HER-2 overexpression in tumors for guiding therapy Curr Pharm Des 14 2999 3019 10.2174/138161208786404290 10.2174/138161208786404290 1:CAS:528:DC%2BD1MXmt1ehtA%3D%3D 18991715
6. JS Ross JA Fletcher GP Linette J Stec E Clark M Ayers, et al. 2003 The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy Oncologist 8 307 325 10.1634/theoncologist.8-4-307 10.1634/ theoncologist.8-4-307 1:CAS:528:DC%2BD3sXmvFSqt74%3D 12897328 (Pubitemid 36929717)
7. E Verri P Guglielmini M Puntoni L Perdelli A Papadia P Lorenzi, et al. 2005 HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study Oncology 68 154 161 10.1159/000086958 10.1159/000086958 1:CAS:528: DC%2BD2MXntFSntbg%3D 16020953 (Pubitemid 41158970)
8. EV Høgdall L Christensen SK Kjaer J Blaakaer JE Bock E Glud, et al. 2003 Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study Cancer 98 66 73 10.1002/cncr.11476 10.1002/cncr.11476 12833457 (Pubitemid 36741127)
9. SB Kolla A Seth MK Singh NP Gupta AK Hemal PN Dogra, et al. 2008 Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy Int Urol Nephrol 40 321 327 10.1007/s11255-007-9283-x 10.1007/s11255-007-9283-x 17899426
10. H Nakamura N Kawasaki M Taguchi K Kabasawa 2005 Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis Cancer 103 1865 1873 10.1002/cncr.20957 10.1002/cncr.20957 1:CAS:528: DC%2BD2MXktFGnsbc%3D 15770690 (Pubitemid 40563259)
11. RC Bast Jr P Ravdin DF Hayes S Bates H Fritsche Jr JM Jessup, et al. 2001 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 1865 1878 11251019
12. 99mTc labeling of highly potent small peptides Bioconjug Chem 8 621 636 10.1021/bc970058b 10.1021/bc970058b 1:CAS:528:DyaK2sXlslGmsrc%3D 9327124 (Pubitemid 27416074)
13. S Liu 2008 Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides Adv Drug Deliv Rev 60 1347 1370 10.1016/j.addr.2008.04.006 10.1016/j.addr.2008.04.006 1:CAS:528:DC%2BD1cXoslWktr8%3D 18538888
14. H Lundqvist V Tolmachev 2002 Targeting peptides and positron emission tomography Biopolymers 66 381 392 10.1002/bip. 10348 10.1002/bip.10348 1:CAS:528:DC%2BD3sXislOqsbo%3D 12658725
15. S Ahlgren A Orlova D Rosik M Sandström A Sjöberg B Baastrup, et al. 2008 Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules Bioconjug Chem 19 235 243 10.1021/bc700307y 10.1021/bc700307y 1:CAS:528:DC%2BD1cXntV2g 18163536 (Pubitemid 351213855)
16. 99mTc to tumor-targeting Affibody molecules Bioconjug Chem 18 549 558 10.1021/bc060291m 10.1021/bc060291m 1:CAS:528:DC%2BD2sXisVGmu7c%3D 17330952 (Pubitemid 46493528)
17. 99mTc-labeled recombinant Affibody molecule ZHER2:2395 with C-terminally engineered cysteine J Nucl Med 50 781 789 10.2967/jnumed.108.056929 1:CAS:528:DC%2BD1MXmtV2hsrw%3D 19372467
18. T Engfeldt A Orlova T Tran A Bruskin C Widström AE Karlström, et al. 2007 Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence Eur J Nucl Med Mol Imaging 34 722 733 10.1007/s00259-006-0266-4 10.1007/s00259-006-0266-4 1:CAS:528:DC%2BD2sXks1agsLY%3D 17146656 (Pubitemid 46669355)
19. T Engfeldt T Tran A Orlova C Widström J Feldwisch L Abrahmsen, et al. 2007 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule Eur J Nucl Med Mol Imaging 34 1843 1853 10.1007/s00259-007-0474-6 10.1007/s00259-007-0474-6 1:CAS:528:DC%2BD2sXhtFylu7zO 17565496 (Pubitemid 47599054)
20. 99mTc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors Bioconjug Chem 18 1956 1964 10.1021/bc7002617 10.1021/bc7002617 1:CAS:528:DC%2BD2sXhtF2gsrvF 17944527 (Pubitemid 350219996)
21. T Ekblad T Tran A Orlova C Widström J Feldwisch L Abrahmsén, et al. 2008 Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake Eur J Nucl Med Mol Imaging 35 2245 2255 10.1007/s00259-008-0845-7 10.1007/s00259-008-0845-7 1:CAS:528: DC%2BD1cXhsVyls73J 18594815
22. TA Tran T Ekblad A Orlova M Sandström J Feldwisch A Wennborg, et al. 2008 Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules Bioconjug Chem 19 2568 2576 10.1021/bc800244b 10.1021/bc800244b 1:CAS:528:DC%2BD1cXhsVemtbzJ 19035668
23. A Orlova V Tolmachev R Pehrson M Lindborg T Tran M Sandström, et al. 2007 Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors Cancer Res 67 2178 2186 10.1158/0008-5472.CAN-06-2887 10.1158/0008-5472.CAN-06-2887 1:CAS:528: DC%2BD2sXitlSjs78%3D 17332348 (Pubitemid 46424237)
24. HER2:342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography Eur J Nucl Med Mol Imaging 35 1008 1018 10.1007/s00259-007-0658-0 10.1007/s00259-007-0658-0 1:CAS:528:DC%2BD1cXkvVyjuro%3D 18157531
25. E Mume A Orlova B Larsson AS Nilsson FY Nilsson S Sjöberg, et al. 2005 Evaluation of ((4-hydroxyphenyl)ethyl) maleimide for site-specific radiobromination of anti-HER2 affibody Bioconjug Chem 16 1547 1555 10.1021/bc050056o 10.1021/bc050056o 1:CAS:528:DC%2BD2MXhtFCmtb3K 16287254 (Pubitemid 41683137)
26. V Tolmachev E Mume S Sjöberg FY Frejd A Orlova 2009 Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules Eur J Nucl Med Mol Imaging 36 692 701 10.1007/s00259-008-1003-y 19066886
27. MW Brechbiel 2008 Bifunctional chelates for metal nuclides Q J Nucl Med Mol Imaging 52 166 173 1:STN:280:DC%2BD1c7pt1WlsA%3D%3D 18043537
28. LM De León-Rodríguez Z Kovacs 2008 The synthesis and chelation chemistry of DOTA-peptide conjugates Bioconjug Chem 19 391 402 10.1021/bc700328s 10.1021/bc700328s 18072717 (Pubitemid 351294908)
29. K Tanaka K Fukase 2008 PET (positron emission tomography) imaging of biomolecules using metal-DOTA complexes: a new collaborative challenge by chemists, biologists, and physicians for future diagnostics and exploration of in vivo dynamics Org Biomol Chem 6 815 828 10.1039/b718157b 10.1039/b718157b 1:CAS:528:DC%2BD1cXit1Sktbc%3D 18292870 (Pubitemid 351653350)
30. MS Ali SM Quadri 1996 Maleimido derivatives of diethylenetriaminepentaacetic acid and triethylenetetraaminehexaacetic acid: their synthesis and potential for specific conjugation with biomolecules Bioconjug Chem 7 576 583 10.1021/bc960051e 10.1021/bc960051e 1:CAS:528:DyaK28XlsVSqur4%3D 8889020 (Pubitemid 26369622)
31. V Tolmachev H Xu H Wållberg S Ahlgren M Hjertman A Sjöberg, et al. 2008 Evaluation of a maleimido derivative of CHX-A"-DTPA for site-specific labeling of affibody molecules Bioconjug Chem 19 1579 1587 10.1021/bc800110y 10.1021/bc800110y 1:CAS:528:DC%2BD1cXosVejtrw%3D 18620447
32. PM Smith-Jones DB Solit T Akhurst F Afroze N Rosen SM Larson 2004 Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors Nat Biotechnol 22 701 706 10.1038/nbt968 10.1038/nbt968 1:CAS:528: DC%2BD2cXksV2gtrs%3D 15133471 (Pubitemid 38702826)
33. GP Adams CC Shaller E Dadachova HH Simmons EM Horak A Tesfaye, et al. 2004 A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice Cancer Res 64 6200 6206 10.1158/0008-5472.CAN-03-2382 10.1158/0008-5472.CAN-03-2382 1:CAS:528:DC%2BD2cXntFClsbc%3D 15342405 (Pubitemid 39136232)